Arbutus Biopharma Corp
Închisă
4.34 0.46
Rezumat
Modificarea prețului
24h
Minim
4.25
Maxim
4.38
Venit | 173M 170M |
|---|---|
Vânzări | 178M 179M |
P/E Medie Sector | 5.398 49.888 |
EPS | 1.19 |
Marjă de profit | 94.735 |
Angajați | 19 |
EBITDA | 177M 169M |
Următoarele câștiguri | 5 aug. 2026 |
|---|
Capitalizare de piață | 20M 885M |
|---|---|
Deschiderea anterioară | 3.88 |
Închiderea anterioară | 4.34 |
Arbutus Biopharma Corp Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Arbutus Biopharma Corp Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
